sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_1574> a bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_1574> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/DRUGBANK:DB00334> ;
    a rdf:Statement ;
    rdfs:label "Olanzapine was FDA approved for the treatment of schizophrenia and bipolar disorder only. It is an atypical antagonist of D2 and D4 receptors which determines a decrease in craving for alcohol. The DRD4 gene of dopamine presents a VNTR polymorphism, with a number of repetitions that varies from 2 to 11 which allows for the division of individuals in two subgroups: those with a number of repetitions between 2 and 6, classified as DRD4 S and those with more than 7 repetitions, classified as DRD4 L. Association studies between this variation and AUD have showed that individuals who carry the L allele exhibit greater craving after alcohol intake,50. Another study has investigated the association olanzapine-DRD4 showing that olanzapine reduces craving to the L allele carriers only, while no benefits were observed in S allele carriers." ;
    bl:has_population_context sub:context ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:publications <https://pubmed.ncbi.nlm.nih.gov/29912214> ;
    bl:relation nkg:OffLabelIndication .
  sub:context a bl:Cohort ;
    rdfs:label "adults" .
  <https://identifiers.org/DRUGBANK:DB00334> a bl:Drug .
}